Press Releases Year All20242023202220212020201920182017201620152014 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 08, 2024 Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 Aug 01, 2024 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction Jun 27, 2024 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors Jun 05, 2024 Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference May 30, 2024 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024 Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan May 09, 2024 Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024
Year All20242023202220212020201920182017201620152014 Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 08, 2024 Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024 Aug 01, 2024 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction Jun 27, 2024 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors Jun 05, 2024 Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference May 30, 2024 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024 Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024 Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan May 09, 2024 Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024
Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update Aug 08, 2024
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction Jun 27, 2024
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 23, 2024
Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA May 23, 2024
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer May 08, 2024
